1 Kessler, R. C. The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. J. Clin. Psychiatry 68 (Suppl. 2), 10–19 (2007).

2 Wittchen, H. U. et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 655–679 (2011). This is a major landmark study that sheds new light on the state of Europe's mental and neurological health.

3 Kessler, R. C. et al. Development of lifetime comorbidity in the World Health Organization world mental health surveys. Arch. Gen. Psychiatry 68, 90–100 (2011).

4 Kessler, R. C. et al. The WHO World Mental Health (WMH) Surveys. Psychiatrie 6, 5–9 (2009).

5 Ormel, J. et al. Disability and treatment of specific mental and physical disorders across the world. Br. J. Psychiatry 192, 368–375 (2008).

6 Kupfer, D. J. & Regier, D. A. Neuroscience, clinical evidence, and the future of psychiatric classification in DSM-5. Am. J. Psychiatry 168, 672–674 (2011).

7 Craddock, N. & Owen, M. J. The Kraepelinian dichotomy — going, going... but still not gone. Br. J. Psychiatry 196, 92–95 (2010).

8 Leucht, S., Heres, S. & Davis, J. M. Considerations about the efficacy of psychopharmacological drugs. Nervenartz 82, 1425–1430 (2011).

9 Caspi, A., Hariri, A. R., Holmes, A., Uher, R. & Moffitt, T. E. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am. J. Psychiatry 167, 509–527 (2010).

10 Owen, D. R., Rupprecht, R. & Nutt, D. J. Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety? J. Psychopharmacol. 27, 119–122 (2013).

11 Nothdurfter, C., Rupprecht, R. & Rammes, G. Recent developments in potential anxiolytic agents targeting GABAA/BzR complex or the translocator protein (18kDa) (TSPO). Curr. Top. Med. Chem. 12, 360–370 (2012).

12 Belzung, C. & Lemoine, M. Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol. Mood Anxiety Disord. 1, 9–14 (2011). This paper refines the concepts of criteria of the validity of anxiety models based on recent developments.

13 Haller, J., Aliczki, M. & Gyimesine, P. K. Classical and novel approaches to the preclinical testing of anxiolytics: a critical evaluation. Neurosci. Biobehav. Rev. http://dx.doi.org/10.1016/j.neubiorev.2012.09.001 (2012).

14 Cryan, J. F. & Holmes, A. The ascent of mouse: advances in modelling human depression and anxiety. Nature Rev. Drug Discov. 4, 775–790 (2005).

15 McKinney, W. T. Jr & Bunney, W. E. Jr. Animal model of depression. I. Review of evidence: implications for research. Arch. Gen. Psychiatry 21, 240–248 (1969).

16 Hall, C. S. Emotional behavior in the rat. I: defecation and urination as measures of individual differences in emotionality. J. Comp. Psychol. 18, 385–403 (1934).

17 Handley, S. L. & Mithani, S. Effects of α-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedeberg Arch. Pharmacol. 327, 1–5 (1984).

18 Crawley, J. N. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol. Biochem. Behav. 15, 695–699 (1981).

19 Lister, R. G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92, 180–185 (1987).

20 Vogel, J. R., Beer, B. & Clody, D. E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21, 1–7 (1971).

21 Geller, I., Kulak, J. T. & Seifter, J. The effects of chlordiazepoxide and chlorpromazine on a punishment discrimination. Psychopharmacologia 3, 374–385 (1962).

22 Griebel, G. & Beeské, S. in Mood and Anxiety Related Phenotypes in Mice (ed. Gould, T. D.) 97–106 (Springer, 2011).

23 Blanchard, D. C., Griebel, G. & Blanchard, R. J. The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic. Eur. J. Pharmacol. 463, 97–116 (2003).

24 Rodgers, R. J., Cao, B. J., Dalvi, A. & Holmes, A. Animal models of anxiety: an ethological perspective. Braz. J. Med. Biol. Res. 30, 289–304 (1997).

25 Steckler, T. & Risbrough, V. Pharmacological treatment of PTSD — established and new approaches. Neuropharmacology 62, 617–627 (2012).

26 Mozhui, K. et al. Strain differences in stress responsivity are associated with divergent amygdala gene expression and glutamate-mediated neuronal excitability. J. Neurosci. 30, 5357–5367 (2010).

27 Belzung, C., El Hage, W., Moindrot, N. & Griebel, G. Behavioral and neurochemical changes following predatory stress in mice. Neuropharmacology 41, 400–408 (2001).

28 Muigg, P. et al. Differential stress-induced neuronal activation patterns in mouse lines selectively bred for high, normal or low anxiety. PLoS ONE 4, e5346 (2009).

29 Holmes, A. & Singewald, N. Individual differences in recovery from traumatic fear. Trends Neurosci. 36, 23–31 (2013).

30 Holmes, A. Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci. Biobehav. Rev. 32, 1293–1314 (2008).

31 Holmes, A. J. et al. Individual differences in amygdala-medial prefrontal anatomy link negative affect, impaired social functioning, and polygenic depression risk. J. Neurosci. 32, 18087–18100 (2012).

32 Donaldson, Z. R., Nautiyal, K. M., Ahmari, S. E. & Hen, R. Genetic approaches for understanding the role of serotonin receptors in mood and behavior. Curr. Opin. Neurobiol. 23, 399–406 (2013).

33 Holmes, A. Targeted gene mutation approaches to the study of anxiety-like behavior in mice. Neurosci. Biobehav. Rev. 25, 261–273 (2001).

34 Tye, K. M. & Deisseroth, K. Optogenetic investigation of neural circuits underlying brain disease in animal models. Nature Rev. Neurosci. 13, 251–266 (2012).

35 Tye, K. M. et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 471, 358–362 (2011).

36 Johansen, J. P. et al. Optical activation of lateral amygdala pyramidal cells instructs associative fear learning. Proc. Natl Acad. Sci. USA 107, 12692–12697 (2010).

37 Fisher, P. M. & Hariri, A. R. Linking variability in brain chemistry and circuit function through multimodal human neuroimaging. Genes Brain Behav. 11, 633–642 (2012).

38 Holmes, A. & Quirk, G. J. Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders — the case of yohimbine. Trends Pharmacol. Sci. 31, 2–7 (2010).

39 Myers, K. M. & Davis, M. Mechanisms of fear extinction. Mol. Psychiatry 12, 120–150 (2007).

40 Richardson, R., Ledgerwood, L. & Cranney, J. Facilitation of fear extinction by d-cycloserine: theoretical and clinical implications. Learn. Mem. 11, 510–516 (2004).

41 Baldwin, D. S. & Garner, M. in Handbook of Anxiety and Fear (eds Blanchard, R. J., Blanchard, D. C., Griebel, G. & Nutt, D.) 395–411 (Elsevier, 2008).

42 Baldwin, D. S., Ajel, K. I. & Garner, M. Pharmacological treatment of generalized anxiety disorder. Curr. Top. Behav. Neurosci. 2, 453–467 (2010).

43 Hoffman, E. J. & Mathew, S. J. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt. Sinai J. Med. 75, 248–262 (2008). This article reviews the evidence from randomized, placebo-controlled trials and meta-analyses of pharmacological treatments of the main anxiety disorders.

44 Rudolph, U. & Knoflach, F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nature Rev. Drug Discov. 10, 685–697 (2011).

45 VanSteveninck, A. L. et al. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br. J. Clin. Pharmacol. 41, 565–573 (1996).

46 Guldner, J. et al. Bretazenil modulates sleep EEG and nocturnal hormone secretion in normal men. Psychopharmacology 122, 115–121 (1995).

47 de Haas, S. L. et al. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A α2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J. Psychopharmacol. 23, 625–632 (2008).

48 Surhone, L. M., Timpledon, M. T. & Marseken, S. F. Ocinaplon (VDM Publishing House, 2010).

49 de Haas, S. L. et al. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J. Psychopharmacol. 21, 374–383 (2007).

50 Rupprecht, R. et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325, 490–493 (2009).

51 Owen, D. R. et al. Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse 65, 257–259 (2011).

52 Griebel, G. 5-hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther. 65, 319–395 (1995).

53 Lesch, K. P. et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527–1531 (1996).

54 Hariri, A. R. & Holmes, A. Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn. Sci. 10, 182–191 (2006).

55 Belzung, C. & Griebel, G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav. Brain Res. 125, 141–149 (2001).

56 Jacobson, L. H. & Cryan, J. F. Genetic approaches to modeling anxiety in animals. Curr. Top. Behav. Neurosci. 2, 161–201 (2010). This is a comprehensive review on models of anxiety involving targeted manipulation of candidate genes.

57 Goldberg, H. L. & Finnerty, R. J. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am. J. Psychiatry 136, 1184–1187 (1979).

58 Rickels, K. et al. Buspirone and diazepam in anxiety: a controlled study. J. Clin. Psychiatry 43, 81–86 (1982).

59 Akimova, E., Lanzenberger, R. & Kasper, S. The serotonin-1A receptor in anxiety disorders. Biol. Psychiatry 66, 627–635 (2009).

60 Goodfellow, N. M., Benekareddy, M., Vaidya, V. A. & Lambe, E. K. Layer II/III of the prefrontal cortex: Inhibition by the serotonin 5-HT1A receptor in development and stress. J. Neurosci. 29, 10094–10103 (2009).

61 Zhang, J. et al. Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors. J. Neurosci. 30, 2433–2441 (2010).

62 Chessick, C. A. et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst. Rev. 2006, CD006115 (2006).

63 Gammans, R. E., Mayol, R. F. & LaBudde, J. A. Metabolism and disposition of buspirone. Am. J. Med. 80, 41–51 (1986).

64 Nutt, D. J. & Ballenger, J. C. Anxiety Disorders (Blackwell Science, 2003).

65 Kent, J. M., Coplan, J. D. & Gorman, J. M. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol. Psychiatry 44, 812–824 (1998).

66 Nutt, D. J. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 10, 49–56 (2005).

67 Gartside, S. E., Umbers, V., Hajos, M. & Sharp, T. Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol. 115, 1064–1070 (1995).

68 Vaswani, M., Linda, F. K. & Ramesh, S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 85–102 (2003).

69 Crabbe, J. C., Wahlsten, D. & Dudek, B. C. Genetics of mouse behavior: interactions with laboratory environment. Science 284, 1670–1672 (1999). This study demonstrates that almost undetectable environmental differences may have large behavioural consequences when using anxiety tests.

70 Handley, S. L. & McBlane, J. W. An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J. Pharmacol. Toxicol. Methods 29, 129–138 (1993).

71 Sanger, D. J. Effects of buspirone and related compounds on suppressed operant responding in rats. J. Pharmacol. Exp. Ther. 254, 420–426 (1990).

72 Maier, S. F. & Watkins, L. R. Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci. Biobehav. Rev. 29, 829–841 (2005).

73 Stein, D. J., Ahokas, A. A., & de Bodinat, C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 28, 561–566 (2008).

74 Belzung, C., Yalcin, I., Griebel, G., Surget, A. & Leman, S. Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders. CNS Neurol. Disord. Drug Targets 5, 135–145 (2006).

75 Holmes, A., Heilig, M., Rupniak, N. M., Steckler, T. & Griebel, G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci. 24, 580–588 (2003).

76 van den Pol, A. N. Neuropeptide transmission in brain circuits. Neuron 76, 98–115 (2012).

77 Steckler, T. Developing small molecule nonpeptidergic drugs for the treatment of anxiety disorders: is the challenge still ahead? Curr. Top. Behav. Neurosci. 2, 415–428 (2010).

78 Griebel, G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol. Ther. 82, 1–61 (1999).

79 Van der Haegen, J. J., Signeau, J. C. & Gepts, W. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 257, 604–605 (1975).

80 Moran, T. H., Robinson, P. H., Goldrich, M. S. & McHugh, P. R. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. 362, 175–179 (1986).

81 Griebel, G. & Holsboer, F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nature Rev. Drug Discov. 11, 462–478 (2012).

82 Vale, W. W., Spiess, J., Rivier, C. & Rivier, J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin. Science 213, 1394–1397 (1981).

83 Chalmers, D. T., Lovenberg, T. W. & De Souza, E. B. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J. Neurosci. 15, 6340–6350 (1995).

84 Turiault, M., Cohen, C. & Griebel, G. in Encyclopedia of Psychopharmacology (ed. Stolerman, I. P.) 1301–1303 (Springer-Verlag, 2010).

85 Regoli, D., Boudon, A. & Fauchere, J. L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46, 551–599 (1994).

86 Griebel, G. & Beeske, S. Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases? Pharmacol. Ther. 133, 116–123 (2012).

87 Brothers, S. P. & Wahlestedt, C. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol. Med. 2, 429–439 (2010).

88 Civelli, O. The orphanin FQ/nociceptin (OFQ/N) system. Results Probl. Cell Differ. 46, 1–25 (2008).

89 Lang, R., Gundlach, A. L. & Kofler, B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol. Ther. 115, 177–207 (2007).

90 Shimazaki, T., Yoshimizu, T. & Chaki, S. Melanin-concentrating hormone MCH1 receptor antagonists: a potential new approach to the treatment of depression and anxiety disorders. CNS Drugs 20, 801–811 (2006).

91 Chung, S. et al. The melanin-concentrating hormone (MCH) system modulates behaviors associated with psychiatric disorders. PLoS ONE 6, e19286 (2011).

92 Xu, Y. L. et al. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 43, 487–497 (2004).

93 Sah, R. & Geracioti, T. D. Neuropeptide Y and posttraumatic stress disorder. Mol. Psychiatry 18, 646–655 (2013).

94 Krystal, J. H. et al. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 24, 669–693 (2010).

95 Dunayevich, E. et al. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33, 1603–1610 (2008).

96 Bergink, V. & Westenberg, H. G. Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740. Int. Clin. Psychopharmacol. 20, 291–293 (2005).

97 Sanacora, G., Zarate, C. A., Krystal, J. H. & Manji, H. K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Rev. Drug Discov. 7, 426–437 (2008).

98 Ressler, K. J. et al. Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry 61, 1136–1144 (2004).

99 Norberg, M. M., Krystal, J. H. & Tolin, D. F. A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biol. Psychiatry 63, 1118–1126 (2008).

100 Herkenham, M. et al. Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA 87, 1932–1936 (1990).

101 Gunduz-Cinar, O. et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol. Psychiatry 18, 813–823 (2013).

102 Neumeister, A. et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol. Psychiatry http://dx.doi.org/10.1038/mp.2013.61 (2013).

103 Griebel, G., Stemmelin, J. & Scatton, B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 57, 261–267 (2005).

104 Jacob, W. et al. Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav. 8, 685–698 (2009).

105 Haller, J., Varga, B., Ledent, C. & Freund, T. F. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav. Pharmacol. 15, 299–304 (2004).

106 Moreira, F. A. & Wotjak, C. T. Cannabinoids and anxiety. Curr. Top. Behav. Neurosci. 2, 429–450 (2010).

107 Metna-Laurent, M. et al. Bimodal control of fear-coping strategies by CB1 cannabinoid receptors. J. Neurosci. 32, 7109–7118 (2012).

108 Topol, E. J. et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 376, 517–523 (2010).

109 Hill, M. N. et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol. Psychiatry http://dx.doi.org/10.1038/mp.2012.90 (2012).

110 Bortolato, M. & Piomelli, D. in Handbook of Anxiety and Fear (eds Blanchard, R. J., Blanchard, D. C., Griebel, G. & Nutt, D.) 303–324 (Elsevier, 2008).

111 Micale, V. et al. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol. Ther. 138, 18–37 (2013).

112 Collins, P. Y. et al. Grand challenges in global mental health. Nature 475, 27–30 (2011).

113 Rodgers, R. J. Animal models of 'anxiety': where next? Behav. Pharmacol. 8, 477–496 (1997).

114 Crestani, F., Martin, J. R., Mohler, H. & Rudolph, U. Resolving differences in GABAA receptor mutant mouse studies. Nature Neurosci. 3, 1059 (2000).

115 Kessler, R. C. et al. Severity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. Arch. Gen. Psychiatry 69, 381–389 (2012).

116 Blanchard, D. C., Griebel, G. & Blanchard, R. J. Gender bias in the preclinical psychopharmacology of anxiety: male models for (predominantly) female disorders. J. Psychopharmacol. 9, 79–82 (1995).

117 Palanza, P. Animal models of anxiety and depression: how are females different? Neurosci. Biobehav. Rev. 25, 219–233 (2001).

118 Soldin, O. P. & Mattison, D. R. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 48, 143–157 (2009).

119 Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nature Chem. Biol. 4, 682–690 (2008).

120 Youdim, M. B. & Buccafusco, J. J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 26, 27–35 (2005).

121 Besnard, J. et al. Automated design of ligands to polypharmacological profiles. Nature 492, 215–220 (2012).

122 Bottegoni, G., Favia, A. D., Recanatini, M. & Cavalli, A. The role of fragment-based and computational methods in polypharmacology. Drug Discov. Today 17, 23–34 (2012).

123 Yizhar, O., Fenno, L. E., Davidson, T. J., Mogri, M. & Deisseroth, K. Optogenetics in neural systems. Neuron 71, 9–34 (2011).

124 Covington, H. E. et al. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J. Neurosci. 30, 16082–16090 (2010).

125 American Psychiatric Association Taskforce on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR (American Psychiatric Association, 2000).

126 Nutt, D. J., Garcia de Miguel, B. & Davies, S. J. C. in Handbook of Anxiety and Fear (eds Blanchard, R. J., Blanchard, D. C., Griebel, G. & Nutt, D. J.) 365–393 (Academic Press, 2008).

127 Reinhold, J. A., Mandos, L. A., Rickels, K. & Lohoff, F. W. Pharmacological treatment of generalized anxiety disorder. Expert. Opin. Pharmacother. 12, 2457–2467 (2011).

128 Kessler, R. C. et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 593–602 (2005).

129 Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R. & Walters, E. E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617–627 (2005).

130 Jeffreys, M., Capehart, B. & Friedman, M. J. Pharmacotherapy for posttraumatic stress disorder: review with clinical applications. J. Rehabil. Res. Dev. 49, 703–715 (2012).

131 Stein, M., Steckler, T., Lightfoot, J. D., Hay, E. & Goddard, A. W. Pharmacologic treatment of panic disorder. Curr. Top. Behav. Neurosci. 2, 469–485 (2010).

132 Kessler, R. C. et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch. Gen. Psychiatry 51, 8–19 (1994).

133 Ganasen, K. A. & Stein, D. J. Pharmacotherapy of social anxiety disorder. Curr. Top. Behav. Neurosci. 2, 487–503 (2010).

134 Abudy, A., Juven-Wetzler, A. & Zohar, J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs 25, 585–596 (2011).

135 Varty, G. B., Morgan, C. A., Cohen-Williams, M. E., Coffin, V. L. & Carey, G. J. The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation. Neuropsychopharmacology 27, 357–370 (2002).

136 Shepherd, J. K., Grewal, S. S., Fletcher, A., Bill, D. J. & Dourish, C. T. Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety. Psychopharmacology 116, 56–64 (1994).

137 Rex, A., Marsden, C. A. & Fink, H. Effect of diazepam on cortical 5-HT release and behaviour in the guinea-pig on exposure to the elevated plus maze. Psychopharmacology 110, 490–496 (1993).

138 Misslin, R., Belzung, C. & Vogel, E. Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents. Behav. Process. 8, 119–132 (1989).

139 de Angelis, L. & File, S. E. Acute and chronic effects of three benzodiazepines in the social interaction anxiety test in mice. Psychopharmacology 64, 127–129 (1979).

140 File, S. E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Methods 2, 219–238 (1980).

141 Thiebot, M. H., Dangoumau, L., Richard, G. & Puech, A. J. Safety signal withdrawal: a behavioural paradigm sensitive to both “anxiolytic” and “anxiogenic” drugs under identical experimental conditions. Psychopharmacology 103, 415–424 (1991).

142 Winslow, J. T. & Insel, T. R. The infant rat separation paradigm: a novel test for novel anxiolytics. Trends Pharmacol. Sci. 12, 402–404 (1991).

143 Vinkers, C. H. et al. Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm. Eur. J. Pharmacol. 585, 407–425 (2008).

144 Boissier, J. R., Simon, P. & Aron, C. A new method for the rapid screening of minor tranquillisers in mice. Eur. J. Pharmacol. 4, 145–151 (1968).

145 Njung'e, K. & Handley, S. L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol. Biochem. Behav. 38, 63–67 (1991).

146 Treit, D., Pinel, J. P. & Fibiger, H. C. Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol. Biochem. Behav. 15, 619–626 (1981).

147 Davis, M. Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm. Behav. Neurosci. 100, 814–824 (1986).

148 Geyer, M. A., Petersen, L. R. & Rose, G. J. Effects of serotonergic lesions on investigatory responding by rats in a holeboard. Behav. Neural. Biol. 30, 160–177 (1980).

149 Bodnoff, S. R., Suranyi Cadotte, B., Aitken, D. H., Quirion, R. & Meaney, M. J. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology 95, 298–302 (1988).

150 Viana, M. B., Tomaz, C. & Graeff, F. G. The elevated T-maze: a new animal model of anxiety and memory. Pharmacol. Biochem. Behav. 49, 549–554 (1994).

151 Espana, J. et al. Intraneuronal β-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol. Psychiatry 67, 513–521 (2010).

152 Richardson-Jones, J. W. et al. Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. J. Neurosci. 31, 6008–6018 (2011).

153 Gleason, G. et al. The serotonin1A receptor gene as a genetic and prenatal maternal environmental factor in anxiety. Proc. Natl Acad. Sci. USA 107, 7592–7597 (2010).

154 Tsetsenis, T., Ma, X. H., Lo, I. L., Beck, S. G. & Gross, C. Suppression of conditioning to ambiguous cues by pharmacogenetic inhibition of the dentate gyrus. Nature Neurosci. 10, 896–902 (2007).

155 Klemenhagen, K. C., Gordon, J. A., David, D. J., Hen, R. & Gross, C. T. Increased fear response to contextual cues in mice lacking the 5-HT1A receptor. Neuropsychopharmacology 31, 101–111 (2005).

156 Li, Q. et al. Medial hypothalamic 5-hydroxytryptamine (5-HT)1A receptors regulate neuroendocrine responses to stress and exploratory locomotor activity: application of recombinant adenovirus containing 5-HT1A sequences. J. Neurosci. 24, 10868–10877 (2004).

157 Bailey, S. J. & Toth, M. Variability in the benzodiazepine response of serotonin 5-HT1A receptor null mice displaying anxiety-like phenotype: evidence for genetic modifiers in the 5-HT-mediated regulation of GABAA receptors. J. Neurosci. 24, 6343–6351 (2004).

158 Pattij, T. et al. Autonomic changes associated with enhanced anxiety in 5-HT1A receptor knockout mice. Neuropsychopharmacology 27, 380–390 (2002).

159 Gross, C. et al. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416, 396–400 (2002).

160 Sibille, E., Pavlides, C., Benke, D. & Toth, M. Genetic inactivation of the serotonin1A receptor in mice results in downregulation of major GABAA receptor α subunits, reduction of GABAA receptor binding, and benzodiazepine-resistant anxiety. J. Neurosci. 20, 2758–2765 (2000).

161 Ramboz, S. et al. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc. Natl Acad. Sci. USA 95, 14476–14481 (1998).

162 Parks, C. L., Robinson, P. S., Sibille, E., Shenk, T. & Toth, M. Increased anxiety of mice lacking the serotonin1A receptor. Proc. Natl Acad. Sci. USA 95, 10734–10739 (1998).

163 Heisler, L. K. et al. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc. Natl Acad. Sci. USA 95, 15049–15054 (1998).

164 Guilloux, J. P. et al. Characterization of 5-HT1A/1B−/− mice: an animal model sensitive to anxiolytic treatments. Neuropharmacology 61, 478–488 (2011).

165 Mombereau, C., Kawahara, Y., Gundersen, B. B., Nishikura, K. & Blendy, J. A. Functional relevance of serotonin 2C receptor mRNA editing in antidepressant- and anxiety-like behaviors. Neuropharmacology 59, 468–473 (2010).

166 Bhatnagar, S. et al. Changes in anxiety-related behaviors and hypothalamic–pituitary–adrenal activity in mice lacking the 5-HT-3A receptor. Physiol. Behav. 81, 545–555 (2004).

167 Bhatnagar, S., Nowak, N., Babich, L. & Bok, L. Deletion of the 5-HT3 receptor differentially affects behavior of males and females in the Porsolt forced swim and defensive withdrawal tests. Behav. Brain Res. 153, 527–535 (2004).

168 Narayanan, V. et al. Social defeat: impact on fear extinction and amygdala-prefrontal cortical theta synchrony in 5-HTT deficient mice. PLoS ONE 6, e22600 (2011).

169 Line, S. J. et al. Opposing alterations in anxiety and species-typical behaviours in serotonin transporter overexpressor and knockout mice. Eur. Neuropsychopharmacol. 21, 108–116 (2011).

170 Heiming, R. S. et al. Living in a dangerous world: the shaping of behavioral profile by early environment and 5-HTT genotype. Front. Behav. Neurosci. 3, 26 (2009).

171 Wellman, C. L. et al. Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J. Neurosci. 27, 684–691 (2007).

172 Carroll, J. C. et al. Effects of mild early life stress on abnormal emotion-related behaviors in 5-HTT knockout mice. Behav. Genet. 37, 214–222 (2007).

173 Ansorge, M. S., Zhou, M., Lira, A., Hen, R. & Gingrich, J. A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306, 879–881 (2004).

174 Lira, A. et al. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol. Psychiatry 54, 960–971 (2003).

175 Holmes, A., Yang, R. J., Lesch, K. P., Crawley, J. N. & Murphy, D. L. Mice lacking the serotonin transporter exhibit 5-HT1A receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 28, 2077–2088 (2003).

176 Hasegawa, S. et al. Transgenic up-regulation of α-CaMKII in forebrain leads to increased anxiety-like behaviors and aggression. Mol. Brain 2, 6 (2009).

177 Ledent, C. et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388, 674–678 (1997).

178 Lähdesmaki, J. et al. Behavioral and neurochemical characterization of α2a-adrenergic receptor knockout mice. Neuroscience 113, 289–299 (2002).

179 Schramm, N. L., McDonald, M. P. & Limbird, L. E. The α2a-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J. Neurosci. 21, 4875–4882 (2001).

180 Okuyama, S. et al. Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor. Brain Res. 821, 150–159 (1999).

181 Ichiki, T. et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377, 748–750 (1995).

182 Raber, J. Role of apolipoprotein E in anxiety. Neural Plast. 2007, 91236 (2007).

183 Dubreucq, S. et al. Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. Neuropsychopharmacology 37, 1885–1900 (2012).

184 Kamprath, K. et al. Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling. Genes Brain Behav. 8, 203–211 (2009).

185 Bura, S. A., Burokas, A., Martin-Garcia, E. & Maldonado, R. Effects of chronic nicotine on food intake and anxiety-like behaviour in CB1 knockout mice. Eur. Neuropsychopharmacol. 20, 369–378 (2010).

186 Tourino, C., Ledent, C., Maldonado, R. & Valverde, O. CB1 cannabinoid receptor modulates 3,4-methylenedioxymethamphetamine acute responses and reinforcement. Biol. Psychiatry 63, 1030–1038 (2008).

187 Kamprath, K. et al. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J. Neurosci. 26, 6677–6686 (2006).

188 Haller, J., Varga, B., Ledent, C., Barna, I. & Freund, T. F. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur. J. Neurosci. 19, 1906–1912 (2004).

189 Marsicano, G. et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530–534 (2002).

190 Haller, J., Bakos, N., Szirmay, M., Ledent, C. & Freund, T. F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 16, 1395–1398 (2002).

191 Maccarrone, M. et al. Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur. J. Neurosci. 15, 1178–1186 (2002).

192 Martin, M., Ledent, C., Parmentier, M., Maldonado, R. & Valverde, O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159, 379–387 (2002).

193 Gogos, J. A. et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl Acad. Sci. USA 95, 9991–9996 (1998).

194 Yamamoto, Y. et al. Increased anxiety behavior in OLETF rats without cholecystokinin-A receptor. Brain Res. Bull. 53, 789–792 (2000).

195 Kobayashi, S., Ohta, M., Miyasaka, K. & Funakoshi, A. Decrease in exploratory behavior in naturally occurring cholecystokinin (CCK)A receptor gene knockout rats. Neurosci. Lett. 214, 61–64 (1996).

196 Abramov, U. et al. Different housing conditions alter the behavioural phenotype of CCK2 receptor-deficient mice. Behav. Brain Res. 193, 108–116 (2008).

197 Miyasaka, K. et al. Anxiety-related behaviors in cholecystokinin-A, B, and AB receptor gene knockout mice in the plus-maze. Neurosci. Lett. 335, 115–118 (2002).

198 Vasar, E. et al. CCKB receptor knockout mice: gender related behavioural differences. Eur. Neuropsychopharmacol. 10 (Suppl. 2), 69 (2000).

199 Chen, Q., Nakajima, A., Meacham, C. & Tang, Y. P. Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse. Proc. Natl Acad. Sci. USA 103, 3881–3886 (2006).

200 Kolber, B. J. et al. Transient early-life forebrain corticotropin-releasing hormone elevation causes long-lasting anxiogenic and despair-like changes in mice. J. Neurosci. 30, 2571–2581 (2010).

201 van Gaalen, M. M., Stenzel-Poore, M. P., Holsboer, F. & Steckler, T. Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur. J. Neurosci. 15, 2007–2015 (2002).

202 Heinrichs, S. C. et al. Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology 22, 215–224 (1997).

203 Stenzel-Poore, M. P., Duncan, J. E., Rittenberg, M. B., Bakke, A. C. & Heinrichs, S. C. CRH overproduction in transgenic mice: behavioral and immune system modulation. Ann. NY Acad. Sci. 780, 36–48 (1996).

204 Stenzel-Poore, M. P., Heinrichs, S. C., Rivest, S., Koob, G. F. & Vale, W. W. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J. Neurosci. 14, 2579–2584 (1994).

205 Ramesh, T. M., Karolyi, I. J., Nakajima, M., Camper, S. A. & Seasholtz, A. F. Altered physiological and behavioral responses in CRH-binding protein deficient mice. Abstr. Soc. Neurosci. 24, 505 (1998).

206 Karolyi, I. J. et al. Altered anxiety and weight gain in corticotropin-releasing hormone-binding protein-deficient mice. Proc. Natl Acad. Sci. USA 96, 11595–11600 (1999).

207 Refojo, D. et al. Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 333, 1903–1907 (2011).

208 Kishimoto, T. et al. Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nature Genet. 24, 415–419 (2000).

209 Coste, S. C. et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nature Genet. 24, 403–409 (2000).

210 Bale, T. L. et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nature Genet. 24, 410–414 (2000).

211 Umehara, F. et al. Elevated anxiety-like and depressive behavior in Desert hedgehog knockout male mice. Behav. Brain Res. 174, 167–173 (2006).

212 Dulawa, S. C., Grandy, D. K., Low, M. J., Paulus, M. P. & Geyer, M. A. Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J. Neurosci. 19, 9550–9556 (1999).

213 Ogawa, S., Lubahn, D. B., Korach, K. S. & Pfaff, D. W. Behavioral effects of estrogen receptor gene disruption in male mice. Proc. Natl Acad. Sci. USA 94, 1476–1481 (1997).

214 Spencer, C. M., Alekseyenko, O., Serysheva, E., Yuva-Paylor, L. A. & Paylor, R. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav. 4, 420–430 (2005).

215 Miyakawa, T., Yagi, T., Watanabe, S. & Niki, H. Increased fearfulness of Fyn tyrosine kinase deficient mice. Brain Res. Mol. Brain Res. 27, 179–182 (1994).

216 Sonner, J. M. et al. α1 subunit-containing GABA type A receptors in forebrain contribute to the effect of inhaled anesthetics on conditioned fear. Mol. Pharmacol. 68, 61–68 (2005).

217 Dixon, C. I., Rosahl, T. W. & Stephens, D. N. Targeted deletion of the GABRA2 gene encoding α2-subunits of GABAA receptors facilitates performance of a conditioned emotional response, and abolishes anxiolytic effects of benzodiazepines and barbiturates. Pharmacol. Biochem. Behav. 90, 1–8 (2008).

218 Hashemi, E., Sahbaie, P., Davies, M. F., Clark, J. D. & Delorey, T. M. Gabrb3 gene deficient mice exhibit increased risk assessment behavior, hypotonia and expansion of the plexus of locus coeruleus dendrites. Brain Res. 1129, 191–199 (2007).

219 Liljelund, P., Ferguson, C., Homanics, G. & Olsen, R. W. Long-term effects of diazepam treatment of epileptic GABAA receptor β3 subunit knockout mouse in early life. Epilepsy Res. 66, 99–115 (2005).

220 Earnheart, J. C. et al. GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. J. Neurosci. 27, 3845–3854 (2007).

221 Homanics, G. E. et al. Normal electrophysiological and behavioral responses to ethanol in mice lacking the long splice variant of the γ2 subunit of the γ-aminobutyrate type A receptor. Neuropharmacology 38, 253–265 (1999).

222 Crestani, F. et al. Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. Nature Neurosci. 2, 833–839 (1999).

223 Chandra, D., Korpi, E. R., Miralles, C. P., De Blas, A. L. & Homanics, G. E. GABAA receptor γ2 subunit knockdown mice have enhanced anxiety-like behavior but unaltered hypnotic response to benzodiazepines. BMC Neurosci. 6, 30 (2005).

224 Mombereau, C. et al. Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits. Neuroreport 16, 307–310 (2005).

225 Mombereau, C., Kaupmann, K., van der Putten, H. & Cryan, J. F. Altered response to benzodiazepine anxiolytics in mice lacking GABAB(1) receptors. Eur. J. Pharmacol. 497, 119–120 (2004).

226 Mombereau, C. et al. Genetic and pharmacological evidence of a role for GABAB receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 29, 1050–1062 (2004).

227 Sangha, S. et al. Deficiency of the 65 kDa isoform of glutamic acid decarboxylase impairs extinction of cued but not contextual fear memory. J. Neurosci. 29, 15713–15720 (2009).

228 Bergado-Acosta, J. R. et al. Critical role of the 65-kDa isoform of glutamic acid decarboxylase in consolidation and generalization of Pavlovian fear memory. Learn. Mem. 15, 163–171 (2008).

229 Stork, O., Yamanaka, H., Stork, S., Kume, N. & Obata, K. Altered conditioned fear behavior in glutamate decarboxylase 65 null mutant mice. Genes Brain Behav. 2, 65–70 (2003).

230 Stork, O. et al. Postnatal development of a GABA deficit and disturbance of neural functions in mice lacking GAD65. Brain Res. 865, 45–58 (2000).

231 Kash, S. F., Tecott, L. H., Hodge, C. & Baekkeskov, S. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc. Natl Acad. Sci. USA 96, 1698–1703 (1999).

232 Chiu, C. S. et al. GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J. Neurosci. 25, 3234–3245 (2005).

233 Holmes, A. et al. Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. Neuropsychopharmacology 28, 1031–1044 (2003).

234 Wei, Q. et al. Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc. Natl Acad. Sci. USA 101, 11851–11856 (2004).

235 Labrie, V. & Roder, J. C. The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 34, 351–372 (2009).

236 Delawary, M. et al. NMDAR2B tyrosine phosphorylation regulates anxiety-like behavior and CRF expression in the amygdala. Mol. Brain 3, 37 (2010).

237 Davis, M. J., Haley, T., Duvoisin, R. M. & Raber, J. Measures of anxiety, sensorimotor function, and memory in male and female mGluR4−/− mice. Behav. Brain Res. 229, 21–28 (2012).

238 Wu, L. J. et al. Increased anxiety-like behavior and enhanced synaptic efficacy in the amygdala of GluR5 knockout mice. PLoS ONE 2, e167 (2007).

239 Linden, A. M. et al. Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor. Neuropharmacology 43, 251–259 (2002).

240 Duvoisin, R. M., Villasana, L., Davis, M. J., Winder, D. G. & Raber, J. Opposing roles of mGluR8 in measures of anxiety involving non-social and social challenges. Behav. Brain Res. 221, 50–54 (2011).

241 Robbins, M. J. et al. Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia. Brain Res. 1152, 215–227 (2007).

242 Sparta, D. R., Fee, J. R., Knapp, D. J., Breese, G. R. & Thiele, T. E. Elevated anxiety-like behavior following ethanol exposure in mutant mice lacking neuropeptide Y (NPY). Drug Alcohol Depend. 90, 297–300 (2007).

243 Duvoisin, R. M. et al. Increased measures of anxiety and weight gain in mice lacking the group III metabotropic glutamate receptor mGluR8. Eur. J. Neurosci. 22, 425–436 (2005).

244 Acevedo, S. F., Pfankuch, T., Ohtsu, H. & Raber, J. Anxiety and cognition in female histidine decarboxylase knockout (Hdc−/−) mice. Behav. Brain Res. 168, 92–99 (2006).

245 Kustova, Y., Sei, Y., Morse, H. C. Jr. & Basile, A. S. The influence of a targeted deletion of the IFNγ gene on emotional behaviors. Brain Behav. Immun. 12, 308–324 (1998).

246 Armario, A., Hernandez, J., Bluethmann, H. & Hidalgo, J. IL-6 deficiency leads to increased emotionality in mice: evidence in transgenic mice carrying a null mutation for IL-6. J. Neuroimmunol. 92, 160–169 (1998).

247 Walther, T. et al. Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J. Biol. Chem. 273, 11867–11873 (1998).

248 Nakamura, E. et al. Disruption of the midkine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal behaviour. Genes Cells 3, 811–822 (1998).

249 Stork, O. et al. Anxiety and increased 5-HT1A receptor response in NCAM null mutant mice. J. Neurobiol. 40, 343–355 (1999).

250 Ross, S. A. et al. Phenotypic characterization of an α4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J. Neurosci. 20, 6431–6441 (2000).

251 Ouagazzal, A. M., Moreau, J. L., Pauly-Evers, M. & Jenck, Z. F. Impact of environmental housing conditions on the emotional responses of mice deficient for nociceptin/orphanin FQ peptide precursor gene. Behav. Brain Res. 144, 111–117 (2003).

252 Frisch, C. et al. Superior water maze performance and increase in fear-related behavior in the endothelial nitric oxide synthase-deficient mouse together with monoamine changes in cerebellum and ventral striatum. J. Neurosci. 20, 6694–6700 (2000).

253 Köster, A. et al. Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc. Natl Acad. Sci. USA 96, 10444–10449 (1999).

254 Gavioli, E. C. et al. Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice. Peptides 28, 1229–1239 (2007).

255 Painsipp, E., Herzog, H., Sperk, G. & Holzer, P. Sex-dependent control of murine emotional-affective behaviour in health and colitis by peptide YY and neuropeptide Y. Br. J. Pharmacol. 163, 1302–1314 (2011).

256 Bannon, A. W. et al. Behavioral characterization of neuropeptide Y knockout mice. Brain Res. 868, 79–87 (2000).

257 Palmiter, R. D., Erickson, J. C., Hollopeter, G., Baraban, S. C. & Schwartz, M. W. Life without neuropeptide Y. Recent Prog. Horm. Res. 53, 163–199 (1998).

258 Inui, A. et al. Anxiety-like behavior in transgenic mice with brain expression of neuropeptide Y. Proc. Assoc. Am. Physicians 110, 171–182 (1998).

259 Karl, T., Burne, T. H. & Herzog, H. Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety. Behav. Brain Res. 167, 87–93 (2006).

260 Konig, M. et al. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383, 535–538 (1996).

261 Osada, T. et al. Increased anxiety and impaired pain response in puromycin-sensitive aminopeptidase gene-deficient mice obtained by a mouse gene-trap method. J. Neurosci. 19, 6068–6078 (1999).

262 Zhao, L. et al. Central nervous system-specific knockout of steroidogenic factor 1 results in increased anxiety-like behavior. Mol. Endocrinol. 22, 1403–1415 (2008).

263 Chrast, R. et al. Mice trisomic for a bacterial artificial chromosome with the single-minded 2 gene (Sim2) show phenotypes similar to some of those present in the partial trisomy 16 mouse models of Down syndrome. Hum. Mol. Genet. 9, 1853–1864 (2000).

264 Sun, Y., Zupan, B., Raaka, B. M., Toth, M. & Gershengorn, M. C. TRH-receptor-type-2-deficient mice are euthyroid and exhibit increased depression and reduced anxiety phenotypes. Neuropsychopharmacology 34, 1601–1608 (2009).

265 Sekiyama, K. et al. Abnormalities in aggression and anxiety in transgenic mice overexpressing activin E. Biochem. Biophys. Res. Commun. 385, 319–323 (2009).

266 Dierssen, M. et al. Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction. Neurobiol. Dis. 24, 403–418 (2006).

267 Fiore, M. et al. Exploratory and displacement behavior in transgenic mice expressing high levels of brain TNF-α. Physiol. Behav. 63, 571–576 (1998).

268 Ehninger, D. & Silva, A. J. Increased levels of anxiety-related behaviors in a Tsc2 dominant negative transgenic mouse model of tuberous sclerosis. Behav. Genet. 41, 357–363 (2011).

269 Bielsky, I. F., Hu, S. B., Ren, X., Terwilliger, E. F. & Young, L. J. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. Neuron 47, 503–513 (2005).

270 Crawley, J. N. & Davis, L. G. Baseline exploratory activity predicts anxiolytic responsiveness to diazepam in five mouse strains. Brain Res. Bull. 8, 609–612 (1982).

271 Crawley, J. N. et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 132, 107–124 (1997).

272 Griebel, G., Belzung, C., Misslin, R. & Vogel, E. The free-exploratory paradigm: an effective method for measuring neophobic behaviour in mice and testing potential neophobia-reducing drugs. Behav. Pharmacol. 4, 637–644 (1993).

273 Pobbe, R. L. et al. General and social anxiety in the BTBR T+ tf/J mouse strain. Behav. Brain Res. 216, 446–451 (2011).

274 Kantor, S., Anheuer, Z. E. & Bagdy, G. High social anxiety and low aggression in Fawn-Hooded rats. Physiol. Behav. 71, 551–557 (2000).

275 Kromer, S. A. et al. Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J. Neurosci. 25, 4375–4384 (2005).

276 Salome, N. et al. Reliability of high and low anxiety-related behaviour: influence of laboratory environment and multifactorial analysis. Behav. Brain Res. 136, 227–237 (2002).

277 Landgraf, R. et al. Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neurosci. Biobehav. Rev. 31, 89–102 (2007).

278 Commissaris, R. L., Harrington, G. M. & Altman, H. J. Benzodiazepine anti-conflict effects in Maudsley reactive (MR/Har) and non-reactive (MNRA/Har) rats. Psychopharmacology 100, 287–292 (1990).

279 Commissaris, R. L., McCloskey, T. C., Harrington, G. M. & Altman, H. J. MR/Har and MNRA/Har Maudsley rat strains: differential response to chlordiazepoxide in a conflict task. Pharmacol. Biochem. Behav. 32, 801–805 (1989).

280 Blizard, D. A. & Adams, N. The Maudsley reactive and nonreactive strains: a new perspective. Behav. Genet. 32, 277–299 (2002).

281 Lopez-Aumatell, R. et al. Unlearned anxiety predicts learned fear: a comparison among heterogeneous rats and the Roman rat strains. Behav. Brain Res. 202, 92–101 (2009).

282 Yilmazer-Hanke, D. M., Faber-Zuschratter, H., Linke, R. & Schwegler, H. Contribution of amygdala neurons containing peptides and calcium-binding proteins to fear-potentiated startle and exploration-related anxiety in inbred Roman high- and low-avoidance rats. Eur. J. Neurosci. 15, 1206–1218 (2002).

283 Steimer, T., Driscoll, P. & Schulz, P. E. Brain metabolism of progesterone, coping behaviour and emotional reactivity in male rats from two psychogenetically selected lines. J. Neuroendocrinol. 9, 169–175 (1997).

284 McAuley, J. D. et al. Wistar-Kyoto rats as an animal model of anxiety vulnerability: support for a hypervigilance hypothesis. Behav. Brain Res. 204, 162–168 (2009).

285 Paré, W. P., Kluczynski, S. M. & Tejani-Butt, S. M. Strain differences in the open field test and the Porsolt forced swim test following antidepressant treatment. Abstr. Soc. Neurosci. 25, 1583 (1999).